Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

subcutaneous

subcutaneous is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 17
Pipeline programs 86
News articles 0
Drug details — subcutaneous
Class
—
Route
—
Patents
17
Programs
86
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

subcutaneous is an FDA-listed pharmaceutical active ingredient.

Key facts

INN subcutaneous

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 206785 Phase 3 · GSK Glaxo Smith · Severe asthma with an eosinophilic phenotype
  2. 221672 Phase 3 · GSK Glaxo Smith · Lung Diseases, Interstitial
  3. 80202135SJS3001 Phase 3 · Janssen-Cilag International N.V · Sjögren's Disease
  4. 80202135SLE3001 Phase 3 · Janssen-Cilag International N.V · Systemic Lupus Erythematosus
  5. CA209-67T Phase 3 · Bristol-Myers Squibb Australia · Metastatic Clear Cell Renal Cell Carcinoma
  6. D3252C00002 Phase 3 · AstraZeneca · Severe CRSwNP patients with asthma.
  7. D3253C00001 Phase 3 · AstraZeneca · Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  8. D3254C00001 Phase 3 · AstraZeneca · Hypereosinophilic Syndrome (HES)

Related patents

Browse patents

  1. US 12371506

    Subcutaneous administration of anti-CD38 antibodies

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12076397

    Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11944618

    Subcutaneous delivery of polymer conjugates of therapeutic agents

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11779635

    Subcutaneous administration of ADAMTS13

    Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11491212

    Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11298350

    Subcutaneous delivery of polymer conjugates of therapeutics agents

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11266724

    Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11242380

    Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11224595

    Subcutaneous delivery of poly(oxazoline) polymer conjugates

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11213524

    Pharmaceutical compositions for subcutaneous administration of levosimendan

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11185575

    Subcutaneous administration of ADAMTS13

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11129940

    Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 2020155578

    Pharmaceutical Formulations for Subcutaneous Administration

    Expires Wed May 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10314837

    Subcutaneous delivery of poly(oxazoline) polymer conjugates

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8952067

    Subcutaneous fat reduction

    Expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8597633

    Subcutaneous delivery of poly(oxazoline) conjugates

    Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8383093

    Subcutaneous delivery of poly(oxazoline) conjugates

    Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is subcutaneous?

subcutaneous is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.